Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
180 participants
OBSERVATIONAL
2012-06-30
2014-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The specific aims of this study are to evaluate overall efficacy and safety of the pre-transplant IVIG treatment in our transplant center since 2007 and to identify factors affecting treatment outcomes in order to improve patient selection and treatment protocols for future patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Proteinuria in Pre and Post Transplant
NCT01094327
Evaluation of Advanced US Tools in Assessing Allograft Complications
NCT04423458
Association of the Intrarenal Resistance Index (RI) of Transplanted Kidneys With Generalized Atherosclerosis
NCT01001065
Expanding Live Donor Kidney Transplantation Through Advocacy Training and Social Media
NCT03099434
Incidence, Risk Factors and Outcomes of Diaphragm Dysfunction After Lung Transplantation
NCT04103996
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Intravenous immunoglobulin (IVIG) infusion is one of several novel approaches to decrease antibody levels for highly sensitized kidney transplant candidates \[1, 2\]. This approach can potentially give a chance of kidney transplantation to end-stage renal failure patients who could never receive transplantation because of high levels of antibodies and persistent positive crossmatches to all potential kidney donors. Many transplant centers have used this strategy in order to increase transplant rates of highly sensitized patients with various levels of anti-HLA antibodies. However, the responses to the treatment seem to be different in each patient and factors affecting treatment outcome have yet to be determined.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Waiting time greater than 1 year for blood type AB, 2 years for blood types A, B, or O.
Exclusion Criteria
* Subject has an uncontrolled concomitant infection or any other unstable medical condition (e.g., uncontrolled cardiovascular disease) that could interfere with the study objectives.
* Subject has an uncontrolled active hepatitis B, hepatitis C, or HIV infection.
* Subject has a current malignancy or a recent history of any malignancy that is deemed to be contraindicated to kidney transplantation.
* Subject has a psychiatric illness that, in the judgment of caring physicians, may interfere with study participation.
7 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Miami
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Junichiro Sageshima
Associate Professor of Clinical
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Junichiro Sageshima, M.D.
Role: PRINCIPAL_INVESTIGATOR
University of Miami
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Miami
Miami, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20120052
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.